For a decade, crop genetics was a science story: CRISPR papers, trait pipelines, regulatory limbo, and the promise that gene-edited crops were always “a few years away.” Over the past three months, the iGrow News database recorded a different kind of story. The genetics layer stopped being a lab and started being an asset — bought, licensed, spun out, and financed at scale. This edition is about who is moving on the seed and trait layer, with what money, and why the smart capital is treating germplasm as the part of agriculture worth owning.

Crop genomics and seed genetics sit at the base of the agricultural value chain: the germplasm, traits, and breeding platforms that determine yield, disease resistance, and climate tolerance before a single input is applied in the field. It is a slow, capital-heavy, IP-driven business — traditional breeding takes 12 to 15 years to produce a new variety — dominated by a handful of majors (Bayer, Corteva, Syngenta, Limagrain) and a rising tier of gene-editing specialists.

As of this week, the database has logged 33 entries across the genetics-and-seed cluster since mid-May: 15 tagged Crop Genomics, 11 Crop Science, and 7 Seeds. The activity skewed toward deals and licensing rather than pure product launches. By dollar value, the biggest moves clustered in Europe — France, the UK, the Netherlands, and Germany — even though the United States logged more individual entries than any other single country; volume and value are telling different stories here. Disclosed funding into Crop Genomics alone reached about $366 million across four rounds, and that figure hides more than it reveals.